BIRC5 and cancer: In contrast, since survivin is a great target and biomarker, the use of cancer cell-based survivin promoter/regulatory sequence-driven reporter system has the potential to provide a better possibility to find unique and versatile small molecules beyond only inhibition of survivin and thus, such small molecules may exhibit high anticancer efficacy with low toxicity to normal tissue due to cancer-associated or focused inhibition.